Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 from Vantanex is discussed for hair loss treatment. Users share experiences and question its legitimacy.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.

A 17-year-old male is experiencing genetic hair thinning and is considering using finasteride and minoxidil for treatment. He is frustrated with dermatologists' suggestions of vitamins and seeks advice on effective solutions.

Hair loss treatment progress after 7 months using a combination of finasteride, minoxidil, microneedling and pyrithione zinc.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

The user is seeing slow hair regrowth using Minoxidil, Finasteride, a derma roller, vitamins, and zinc. Some suggest switching to dutasteride or adding other treatments, but others doubt significant cosmetic improvement due to advanced hair loss.

The user experienced severe side effects with topical finasteride, continued using Minoxidil, and was advised to try topical dutasteride after a test suggested they might not respond to finasteride. They are hesitant to start the new treatment due to past side effects.

The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.

RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

A 27-year-old man experienced hair regrowth and gynecomastia from finasteride, leading to a cycle of stopping and restarting the treatment. He is considering gyno surgery and consulting an endocrinologist as potential solutions.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

The user experienced hair shedding and follicle shrinkage when using retinoic acid, despite trying different concentrations and frequencies. The hair loss persisted for six months but regrew after stopping the treatment.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.

RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

Using a combination of topical finasteride, minoxidil, caffeine and dermaroller treatments to help with hair loss, while discussing the potential results and other options.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The user has been using finasteride and minoxidil for over 7 years, switched to dutasteride 3 years ago, and is satisfied with the results. They experienced no noticeable side effects and use minoxidil on their hairline and temples.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

The user shared their positive experience with finasteride for hair loss over seven years, noting it stopped hair recession and maintained their hairline. They also mentioned using minoxidil irregularly and experiencing a lower sperm count but no erectile dysfunction.

The user switched from finasteride to dutasteride and is using minoxidil and RU58841 for hair loss treatment. They are satisfied with the progress and considering a hair transplant, despite some initial shedding after the medication change.

The conversation discusses alternative hair growth treatments to minoxidil, including Stemoxydine, Tretinoin, adenosine, Baicalin, castor oil, Latanoprost/bimatoprost, and Redensyl. Users share their experiences and opinions on the efficacy of these treatments.

A man stopped taking finasteride, a hair loss treatment, to improve his fertility. His sperm count and motility increased after stopping the medication, but sperm shape did not change.

A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.